NATIONAL INSTITUTES OF HEALTH

Eisai and Biogen launch LEQEMBI, a humanized anti-amyloid-beta monoclonal antibody, in South Korea for treating Alzheimer's disease, targeting soluble and insoluble Abeta aggregates to reduce cognitive decline.

SeniorsPlus to launch a $5.5 million capital campaign on December 3 to build a new education and nutrition center at 14 Mollison Way, designed to combat isolation among older adults.

Eisai launches Leqembi in South Korea for mild cognitive impairment due to Alzheimer's disease. Leqembi selectively binds to amyloid-beta aggregates, reducing disease progression and cognitive decline. Developed by BioArctic and Eisai, it's the first treatment to show efficacy through this mechanism.

Dana-Farber researchers developed a machine learning model using genomic heterogeneity and ploidy to predict resistance to anti-PD-1 therapy in metastatic melanoma, validated in four cohorts. The model suggests 43% of predicted resistant patients respond to combination therapy, potentially guiding treatment choices.

Eisai and Biogen launch LEQEMBI, a humanized anti-soluble aggregated amyloid-beta monoclonal antibody, in South Korea for treating mild cognitive impairment due to Alzheimer's disease or mild AD dementia. LEQEMBI selectively binds to soluble and insoluble Aβ aggregates, reducing both protofibrils and plaques in the brain, and is the first treatment shown to slow cognitive and functional decline through this mechanism.

Eisai and Biogen launch LEQEMBI in South Korea, a humanized anti-soluble aggregated amyloid-beta monoclonal antibody for mild cognitive impairment due to Alzheimer's disease or mild AD dementia. LEQEMBI selectively binds to soluble and insoluble Aβ aggregates, reducing both protofibrils and plaques in the brain, and is the first treatment shown to slow cognitive and functional decline.

NIH developed AI algorithm TrialGPT to match potential volunteers for clinical trials, reducing screening time by 40% while maintaining accuracy. The tool aims to enhance trial recruitment and reduce participation barriers for underrepresented populations.